The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma
Authors:
- 3 November 2010
- journal article
- research article
- Published by Springer Nature in Pediatric Surgery International
- Vol. 27 (3) , 231-236
Abstract
MYCN amplification (MYCN-A) is a strong prognostic factor in neuroblastoma (NB). MYCN gain which is a low level of MYCN-A as determined by FISH. It is unclear whether the MYCN gain is the pre-status of MYCN-A. This study assessed the status of MYCN gene and chromosome 2p of MYCN-A, MYCN gain and no MYCN amplification using a single nucleotide polymorphism (SNP) array, and the clinical implication of MYCN gain in NB. The status of the MYCN gene was determined by FISH in 47 primary NB samples and the status of chromosome 2p in all cases was analyzed using an SNP array. 8 of the 47 cases analyzed using FISH showed MYCN-A, 7 cases showed MYCN gain and 32 cases showed no MYCN amplification. An SNP array analysis showed that only 2 of 8 cases with MYCN-A by FISH had both amplification of MYCN region and distal 2p gain and other 6 cases had amplification of the MYCN region without distal 2p gain. All 7 cases with MYCN gain by FISH had distal 2p gain without amplification of the MYCN region, and all 32 cases with no MYCN amplification by FISH demonstrated neither the amplification of the MYCN region nor the 2p gain. 5-year overall survival rate of patients with MYCN gain (n = 7, 71.4%) was not significant different from that of patients with no MYCN amplification (n = 32, 90.6%) by FISH (p = 0.11). These results suggested that the MYCN gain detected by FISH represents the 2p gain, and the MYCN gain is not considered to represent the pre-status of MYCN amplification.Keywords
This publication has 19 references indexed in Scilit:
- Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCRPediatric Surgery International, 2008
- High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A geneBMC Genomics, 2008
- Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplificationBritish Journal of Cancer, 2007
- Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival dataOncogene, 2007
- Prediction of MYCN Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain ReactionJournal of Clinical Oncology, 2005
- Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines*†Medical and Pediatric Oncology, 2001
- Allelic deletion at 11q23 is common in MYCN single copy neuroblastomasOncogene, 1999
- Biology and Genetics of Human NeuroblastomasJournal of Pediatric Hematology/Oncology, 1997
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984